Phosphoinositide 3-kinase inhibitor

Phosphoinositide 3-kinase inhibitors (PI3K inhibitors) are a class of drugs that function by inhibiting one or more of the phosphoinositide 3-kinases (PI3Ks), which are enzymes involved in cell cycle regulation and survival. These inhibitors have shown promise in the treatment of cancer, particularly in cases where the disease has become resistant to other forms of therapy.

Mechanism of Action[edit | edit source]

PI3K inhibitors work by blocking the action of PI3Ks, a family of enzymes that play a key role in cell functions such as growth, proliferation, differentiation, motility, survival and intracellular trafficking. The inhibition of these enzymes can lead to the suppression of the PI3K/AKT/mTOR pathway, a signaling pathway that is often overactive in cancer cells.

Clinical Use[edit | edit source]

PI3K inhibitors are primarily used in the treatment of various types of cancer. They have shown efficacy in treating breast cancer, lung cancer, leukemia, and lymphoma, among others. Some of the PI3K inhibitors that are currently approved for use include idelalisib, copanlisib, and duvelisib.

Side Effects[edit | edit source]

Like all drugs, PI3K inhibitors can cause side effects. These can include nausea, diarrhea, fatigue, and rash. More serious side effects can include infection, pneumonitis, and hyperglycemia. It is important for patients to discuss these potential side effects with their healthcare provider before starting treatment.

Research[edit | edit source]

Research into PI3K inhibitors is ongoing, with many clinical trials currently underway to evaluate their efficacy and safety in various types of cancer. This research is crucial for understanding how these drugs can be best used to treat cancer and improve patient outcomes.